Synergy (SGYP) Higher After Plecanatide Meets Endpoints
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/15/2026
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- Fed’s Warsh says central bank won’t tolerate high inflation
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- IBM misses Q2 targets as mainframe and software sales disappoint
- Verizon planning new round of layoffs this week - Barron’s
- Kosovo bans Serb minister over ethnic cleansing remarks
- Lucid Group shares quickly cut in half on report of potential bankruptcy
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
Synergy Pharmaceuticals (SGYP) PT Nearly Doubled at Cantor Fitzgerald
January 2, 2013 12:44 PM ESTCantor Fitzgerald raised its price target on Buy-rated Synergy Pharmaceuticals (NASDAQ: SGYP) from $7 to $13 following positive top-line results from its Phase IIb/III chronic constipation (CC) trial of plecanatide.
The firm comments, "While details were not disclosed since the company is attempting to... More
